A phase 3, double-blind study evaluated the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of moderate-to-severe atopic dermatitis in Japanese patients from the ages of 12 to 75. Patients received 15 mg of upadacitinib 1 TCS, 30 mg of upadacitinib 1 TCS, or a placebo 1 TCS (rerandomized in a 1:1 ratio to receive either 15 or 30 mg of upadacitinib 1 TCS at week 16).
Learn more at the Journal of the American Academy of Dermatology International.